Agios Pharmaceuticals Inc


Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Outlines Key Upcoming Milestones Amid Evolution To Commercial Stage Biopharmaceutical Company

Agios Pharmaceuticals Inc (NASDAQ:AGIO) outlined key 2017 milestones in conjunction with its presentation at the 35th Annual J.P.

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Appoints Ian Clark to Board of Directors

Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced the appointment of Ian Clark to its board of directors. Most recently, Mr.

Canaccord Lays Out the Bullish Case for Agios Pharmaceuticals Inc (AGIO) Despite IND Withdrawal

Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares were thundering down 19% yesterday after news came to light that the firm has withdrawn its Investigational New …

Canaccord Chimes In On Agios Pharmaceuticals Inc (AGIO) Following ASH Event

In a research report published Monday, Canaccord analyst John Newman reiterated a Buy rating on shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO), with a …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Announces Proposed Offering of Common Stock

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced that it is offering to sell, subject to market and other conditions, up to $150 million of its …

Canaccord Positive on Agios Pharmaceuticals Inc (AGIO) on Back of NDA Filing

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced that its collaboration partner Celgene Corporation (NASDAQ:CELG) intends to file for an NDA for its AML-treating drug AG-221 …

Company Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Appoints Andrew Hirsch as Chief Financial Officer

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, announced that Andrew Hirsch is joining the …

Company Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced the initial data from the Phase 1 integrated single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of …

Stock Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results …

Monday’s Mid-Day Movers: American Midstream Partners LP (AMID), Tenet Healthcare Corp (THC), Glu Mobile Inc. (GLUU), and Agios Pharmaceuticals Inc (AGIO)

American Midstream Partners LP (NYSE:AMID) is up more than 35% at mid-day after the pipeline company announced a $75 million unit purchase program, …